Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 13, 2025
Finance

Newleos launches with $93.5M, neuropsychiatry candidates from Roche: Venture Report

Plus: DeepMind veterans raise $50M for AI-guided protein design start-up; crossovers back Abcuro’s pivotal study; and more
BioCentury | Aug 17, 2023
Emerging Company Profile

How Abcuro is targeting specific T cells to treat a rare muscle-wasting disease

Crossovers back company in $155M round to advance KLRG1 program for inclusion body myositis
BioCentury | Mar 29, 2022
Data Byte

Pyxis-Biosion deal readies anti-SIGLEC15 mAb for clinic behind NextCure program

U.S.-based Pyxis takes rights to SIGLEC15 program that would trail NextCure’s candidate
Items per page:
1 - 4 of 4